| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | BIM is a prognostic biomarker for early prednisolone response in pediatric acute lymphoblastic leukemia. | Exp Hematol | 2010 | 1.04 |
| 2 | Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL). | Pediatr Blood Cancer | 2006 | 0.80 |